MEPOLIZUMAB

mepolizumab 100 mg/mL injection, 1 mL pen device

MEPOLIZUMAB (13242Y)

mepolizumab 100 mg/mL injection, 1 mL pen device
13242Y
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Chronic rhinosinusitis with nasal polyps (CRSwNP)
Treatment phase: Initial treatment

Restriction

Indication: Chronic rhinosinusitis with nasal polyps (CRSwNP)
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $1,604.98 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Nucala